HuGE Literature Finder
Records
1
-
18
| Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study. Frontiers in pharmacology 2022 12 13 1032995. Azzahhafi Jaouad, Bergmeijer Thomas O, van den Broek Wout W A, Chan Pin Yin Dean R P P, Rayhi Senna, Peper Joyce, Bor Willem L, Claassens Daniel M F, van Schaik Ron H N, Ten Berg Jurriën |
| Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
| Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2020 4 25 (4): 331-340. Torres Espíndola Luz María, Rojo-Serrato Daniela, Álvaro-Heredia Antonio, Castillejos López Manuel de Jesús, de Uña-Flores Armando, Pérez-García Martin, Zapata-Tarres Marta, Cárdenas-Cardos Rocio, Granados Julio, Chávez-Pacheco Juan Luis, Salinas-Lara Citlaltepetl, de Arellano Israel Torres-Ramirez, Aquino-Gálvez Arnol |
| CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. Pharmacogenomics and personalized medicine 2020 3 13 29-37. Sychev D A, Baturina O A, Mirzaev K B, Rytkin E, Ivashchenko D V, Andreev D A, Ryzhikova K A, Grishina E A, Bochkov P O, Shevchenko R |
| Toward precision prescribing for methadone: Determinants of methadone deposition. PloS one 2020 15 (4): e0231467. Talal Andrew H, Ding Yuxin, Venuto Charles S, Chakan Lindsay M, McLeod Anthony, Dharia Arpan, Morse Gene D, Brown Lawrence S, Markatou Marianthi, Kharasch Evan |
| Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma. Journal of bone oncology 2018 Sep 12 44-48. Xu Leilei, Xia Chao, Sun Qi, Sheng Fei, Xiong Jin, Wang Shoufe |
| Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population. Clinical therapeutics 2018 Feb . Peng Chen, Ding Ying, Yi Xin, Shen Yupei, Dong Zhiqiang, Cao Limei, Li Qiang, Ren Haiyan, He Lin, Zhou Daizhan, Chen |
| Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 Sep . Yi Xingyang, Han Zhao, Zhou Qiang, Cheng Wen, Lin Jing, Wang Ch |
| Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2016 Aug . Yi Xingyang, Zhou Qiang, Wang Chun, Lin Jing, Cheng Wen, Chi Lif |
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
European heart journal 2015 Aug 36 (29): 1901-12. Varenhorst Christoph, Eriksson Niclas, Johansson Åsa, Barratt Bryan J, Hagström Emil, Åkerblom Axel, Syvänen Ann-Christine, Becker Richard C, James Stefan K, Katus Hugo A, Husted Steen, Steg Ph Gabriel, Siegbahn Agneta, Voora Deepak, Teng Renli, Storey Robert F, Wallentin Lars, |
| Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC. Cardiovascular interventions 2013 Nov 6 (11): 11. Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G |
| The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2013 Jul 9 (3): 316-27. Liang Zhen-Yang, Han Ya-Ling, Zhang Xiao-Lin, Li Yi, Yan Cheng-Hui, Kang Ji |
| Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations. Frontiers in genetics 2012 3 . Roco A, Quiñones L, Agúndez JA, García-Martín E, Squicciarini V, Miranda C, Garay J, Farfán N, Saavedra I, Cáceres D, Ibarra C, Varela N |
| Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart (British Cardiac Society) 2012 Sep 98 (18): 1366-72. Park Kyung Woo, Kang Jeehoon, Park Jin Joo, Yang Han-Mo, Lee Hae-Young, Kang Hyun-Jae, Koo Bon-Kwon, Oh Byung-Hee, Park Young-Bae, Kim Hyo-S |
| Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Forensic science international 2012 Jan 214 (1-3): 124-34. Kingbäck Maria, Karlsson Louise, Zackrisson Anna-Lena, Carlsson Björn, Josefsson Martin, Bengtsson Finn, Ahlner Johan, Kugelberg Fredrik |
| Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. International journal of molecular epidemiology and genetics 2011 2 (2): 185-95. Peethambaram Prema, Fridley Brooke L, Vierkant Robert A, Larson Melissa C, Kalli Kimberly R, Elliott Elaine A, Oberg Ann L, White Kristin L, Rider David N, Keeney Gary L, Cunningham Julie M, Hartmann Lynn C, Goode Ellen |
| CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. British journal of cancer 2003 Mar 88 (6): 928-32. Tayeb M T, Clark C, Haites N E, Sharp L, Murray G I, McLeod H |
| CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology reports 0 9 (3): 653-5. Tayeb Mohammed T, Clark Caroline, Sharp Linda, Haites Neva E, Rooney Patrick H, Murray Graeme I, Payne Simon N L, McLeod Howard |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 31, 2023
- Content source: